21 completed. 21 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 21 |
| Phase 2 | 4 | Completed 4 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio), Inactivated poliomyelitis vaccine (IPOL), VLP-Polio - Poliomyelitis | Phase 1 | Completed | CanSino Biologics Inc. | 72 | 2024-01-15 | 2024-12-04 |
| A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) MT-3921, Placebo - HTLV-1-Associated Myelopathy (HAM) | Phase 1 | Completed | Tanabe Pharma Corporation | 15 | 2022-05-02 | 2024-01-29 |
| Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 1 | Completed | PATH | 226 | 2021-03-26 | 2024-11-20 |
| Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV) - Polio | Phase 1 | Completed | PATH | 87 | 2020-01-22 | 2022-09-06 |
| Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant dmLT, fIPV - Polio | Phase 1 | Completed | University of Vermont | 29 | 2019-03-19 | 2020-08-05 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) sIPV - Polio | Phase 1 / Phase 2 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 60 | 2017-11-24 | 2020-02-11 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine sIPV, Commercialized sIPV, Commercialized IPV - Polio | Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 100 | 2017-08-21 | 2020-02-11 |
| Central Pain Study for ABX-1431 ABX-1431 HCl, Placebo - Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis | Phase 1 | Completed | Abide Therapeutics | 9 | 2017-08-01 | 2019-01-25 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV - Diphtheria, Tetanus | Phase 1 | Completed | LG Chem | 42 | 2017-07-03 | 2019-08-29 |
| Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults Novel OPV2 candidate 1, Novel OPV2 candidate 2 - Poliomyelitis | Phase 1 | Completed | Pierre Van Damme | 30 | 2017-05-16 | 2021-02-04 |
| Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Single-dose regimen of high dosage investigational sIPV, Single-dose regimen of medium dosage investigational sIPV, Three-dose regimen of high dosage investigational sIPV - Poliomyelitis | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 708 | 2016-10-01 | 2017-07-26 |
| Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Ublituximab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 1 | Completed | Johns Hopkins University | 6 | 2016-01-01 | 2019-06-06 |
| Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD), a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®). - Poliomyelitis | Phase 1 | Completed | University Hospital, Ghent | 120 | 2013-11-01 | 2015-11-10 |
| Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) IPV vaccination - Poliomyelitis, Tropical Enteropathy | Phase 1 | Completed | International Vaccine Institute | 372 | 2012-03-01 | 2017-08-31 |
| Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants IPV, Low dose Sabin-IPV, Low dose adjuvanted Sabin-IPV - Poliomyelitis | Phase 1 / Phase 2 | Completed | Pauline Verdijk | 140 | 2012-02-01 | 2014-02-21 |
| Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults IPV, Sabin-IPV, Adjuvanted Sabin-IPV - Poliomyelitis | Phase 1 | Completed | Pauline Verdijk | 45 | 2011-08-01 | 2014-02-21 |
| Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants Poliorix - Poliomyelitis | Phase 1 | Completed | GlaxoSmithKline | 25 | 2009-08-04 | 2018-12-17 |
| The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains Inactivated Poliomyelitis Vaccine (Sabin strains) - Poliomyelitis | Phase 1 | Completed | Chinese Academy of Medical Sciences | 130 | 2008-08-01 | 2010-01-14 |
| Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Hu MiK-Beta-1 - HTLV-1 | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 9 | 2004-02-03 | 2019-06-27 |
| Safety and Tolerability of Rituximab in Neuromyelitis Optica Rituximab - Neuromyelitis Optica | Phase 1 | Completed | University of California, San Francisco | 20 | 2004-01-01 | 2011-09-27 |
Showing 20 of 21. Sign in to see all of them.
Poliomyelitis (15) · Myelitis, Transverse (3) · Neuromyelitis Optica (3) · Paraparesis, Tropical Spastic (2) · Diphtheria (1) · Encephalitis (1) · Haemophilus Infections (1) · Hepatitis B (1) · Multiple Sclerosis (1) · Optic Neuritis (1) · Sprue, Tropical (1) · Tetanus (1) · Whooping Cough (1)
Central Nervous System Diseases (21) · Central Nervous System Infections (21) · Infections (21) · Nervous System Diseases (21) · Neuroinflammatory Diseases (21) · Spinal Cord Diseases (21) · RNA Virus Infections (17) · Virus Diseases (17) · Enterovirus Infections (15) · Neuromuscular Diseases (15) · Picornaviridae Infections (15) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · Cranial Nerve Diseases (3)
Poliovirus Vaccine, Inactivated (6) · Adjuvants, Pharmaceutic (1) · Aging (1) · Hu-Mik-beta-1 monoclonal antibody (1) · LFB-R603 (1) · Rituximab (1) · ublituximab (1)
Jiangsu Province Centers for Disease Control and Prevention (2) · PATH (2) · Pauline Verdijk (2) · Abide Therapeutics (1) · CanSino Biologics Inc. (1) · Chinese Academy of Medical Sciences (1) · GlaxoSmithKline (1) · International Vaccine Institute (1) · Johns Hopkins University (1) · LG Chem (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Pierre Van Damme (1) · Sinovac Biotech Co., Ltd (1) · Tanabe Pharma Corporation (1)
United States (6) · China (5) · Belgium (3) · Poland (2) · Australia (1) · Canada (1) · India (1) · Japan (1) · South Korea (1) · United Kingdom (1)
Beth Kirkpatrick, M.D. (2) · Fengcai Zhu, Master (2) · Pauline Verdijk, PhD (2) · Anu Jacob, MD DM FRCP (1) · Arlene Sena, MD (1) · Ayan Dey, Ph.D (1) · Bruce Cree, MD, PhD (1) · Christina Chang, Dr (1) · Geert Leroux-Roels, MD, PhD (1) · Jacqueline Palace, FRCP DM (1) · Jessica Crothers, MD (1) · Kelly Cowan, M.D. (1) · Li Changgui, PhD (1)
PMID 32867698, PMID 24063976, PMID 25043278, PMID 26873055, PMID 28194449, PMID 30249424, PMID 31174831, PMID 35367069, PMID 36746739, PMID 38218668, PMID 40818478
2017 (1), 2019 (1)